西安可以通过改善B细胞介导的免疫反应来缓解循环胺诱导的免疫抑制
Chengyu Yang1,2, Ya Xu1,2, Fenfang Gong1,2
1Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.
Frontiers in pharmacology
|May 8, 2025
概括
翔 (SXD) 通过增强B细胞免疫力和抑制小鼠的缺氧和衰老途径来改善化疗诱导的免疫抑制.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
背景情况:
- 化疗经常导致免疫抑制,危及患者的健康.
- 西 (SXD) 是一种传统中医药,在缓解化疗诱导的免疫抑制方面显示出有前途.
- 通过SXD调节免疫抑制的确切机制需要进一步研究.
研究的目的:
- 在免疫功能低下的小鼠模型中评估SXD的疗效.
- 阐明SXD治疗效果背后的免疫机制.
主要方法:
- 在小鼠中使用环胺 (CTX) 诱导免疫抑制模型.
- 小鼠接受了不同剂量的SXD提取物治疗.
- 通过流式细胞计量,分析了脏,胸腺和血液的免疫细胞群 (B和T细胞).
- 用RNA测序和生物信息学分析 (GO,KEGG) 来确定SXD调节的基因和途径.
- 评估了B细胞转录因子的蛋白质表达,使用免疫阻塞.
主要成果:
- 在免疫抑制小鼠中,SXD治疗改善了脏和胸腺器官指数和淋巴细胞计数.
- SXD促进了B细胞介导的幽默性免疫反应.
- RNA测序表明,SXD可以提高B细胞免疫力和B细胞受体信号通路的调节.
- SXD增强了B细胞分化因子 (Pax5,Tcf3) 的表达,并促进了脏细胞的增殖.
- 在脏中,SXD显著抑制了缺氧和衰老路径.
结论:
- 在SXD中,它显示出对循环胺诱导的免疫抑制有保护作用.
- SXD的有效性归因于B细胞免疫力的上调.
- 抑制缺氧和衰老途径有助于SXD的免疫调节作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
101
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
101
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86


